Ciprofloxacin/Dexamethasone Otic prior authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization requirements for ciprofloxacin/dexamethasone otic (ear drops) for members under CareOregon Medicaid, specifying approved indications and required prior therapies.
No material clinical or coverage changes in this revision.
Coverage Criteria for Ciprofloxacin/Dexamethasone Otic
inv-01: Initial approval for acute otitis externa
Covered when ALL of the following are met
Approval length: 7 days
inv-02: Approval for post-tympanostomy tube otorrhea / AOMT
Covered when ALL of the following are met
Approval length: 7 days
Requests for use of ciprofloxacin/dexamethasone otic as prophylaxis following tympanostomy tube placement are explicitly excluded from approval. Approval is limited to therapeutic indications meeting the stated criteria (for example, AOMT or post-operative tube otorrhea) and does not cover prophylactic administration after tube insertion.
Provider Requirements and Prior Authorization
Prior authorization and approval length
Prior authorization is required for ciprofloxacin/dexamethasone otic. When the coverage criteria are met, approval is granted for 7 days.
Step therapy requirements
Step therapy requires documented failure of a topical fluoroquinolone (ciprofloxacin or ofloxacin) otic. In addition, the member must have either failed neomycin/polymyxin B/hydrocortisone otic OR have a perforated tympanic membrane or tympanostomy tubes.
- Failure of ciprofloxacin or ofloxacin otic is required.
- Plus one of: failure of neomycin/polymyxin B/hydrocortisone otic OR presence of a perforated tympanic membrane or tympanostomy tubes.
Required documentation
Document the member's diagnosis and prior topical treatment history, including failure of ciprofloxacin or ofloxacin otic; when applicable, document failure of neomycin/polymyxin B/hydrocortisone otic or presence of a perforated tympanic membrane or tympanostomy tubes. For requests related to tympanostomy tube otorrhea, note that requests for prophylaxis following tympanostomy tube placement are excluded.
- Diagnosis: acute otitis externa or acute otitis media with tympanostomy tubes/post-operative tympanostomy tube otorrhea and/or granulation tissue.
- Prior treatment history: failure of ciprofloxacin or ofloxacin otic; if claiming the alternate pathway, failure of neomycin/polymyxin B/hydrocortisone otic or documentation of perforated tympanic membrane/tympanostomy tubes.
- Do not submit requests for prophylaxis after tympanostomy tube placement (these are excluded).
Denial triggers
Requests may be denied if the coverage criteria are not met — for example, if the diagnosis is not acute otitis externa (or the specified AOMT/post-tympanostomy conditions) or if required prior topical therapy failures (ciprofloxacin or ofloxacin otic, and when required neomycin/polymyxin B/hydrocortisone otic) are not documented.
- Missing documentation of failure of ciprofloxacin or ofloxacin otic.
- Missing documentation of failure of neomycin/polymyxin B/hydrocortisone otic when that pathway is claimed.
- Diagnosis not consistent with acute otitis externa or the specified post-tympanostomy indications.
- Requests for prophylaxis following tympanostomy tube placement.
Definitions
Background
Ciprofloxacin/dexamethasone otic is indicated for certain ear infections where topical fluoroquinolone therapy is required. The guideline specifies primary use for acute otitis externa (swimmer’s ear) when the member has failed prior topical ciprofloxacin or ofloxacin, and either has failed neomycin/polymyxin B/hydrocortisone otic or has a perforated tympanic membrane or tympanostomy tubes. It is also an approved option for acute otitis media with tympanostomy tubes (AOMT) or post-operative tympanostomy tube otorrhea/granulation tissue, provided the request is not for prophylaxis following tube placement.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.